Royal Melbourne Hospital

GTG Global Collaborations and Innovation Update

Retrieved on: 
星期二, 三月 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Retrieved on: 
星期一, 九月 11, 2023
Cancer, MRFF, University, Royal Melbourne Hospital, Cancer Australia, Bureau of Oceans and International Environmental and Scientific Affairs, National Guideline Clearinghouse, GTG, The Royal Marsden NHS Foundation Trust, Risk, University of Melbourne, Policy, ASX, Breast, Research, Genomics, Prostate, History, Queen Mary University of London, General practice, Standard of care, Melanoma, Genetypes, Scores, Biostatistics, Health, Medical Research Future Fund, Primary care, Pharmaceutical industry, Vaccine

The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

Key Points: 
  • The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.
  • GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
  • The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
  • As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.

Nurami Medical's ArtiFascia® Dura Substitute Receives FDA Clearance

Retrieved on: 
星期一, 八月 21, 2023
Dural, New South Wales, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, US Foods, Workflow, Infection, Dura mater, Brain, Cerebrospinal fluid, Trial of the century, Royal Melbourne Hospital, Neurosurgery, Regeneration, CSF, FDA, Safety, Food, Nanofiber, Medical device, Silk, Medical imaging

HAIFA, Israel, Aug. 21, 2023 /PRNewswire/ -- Medical device startup NURAMI MEDICAL has received 510(k) clearance from the US Food and Drug Administration (FDA) for its electrospun nanofiber-based product, ArtiFascia® Dura Substitute, a resorbable Dural repair graft.

Key Points: 
  • HAIFA, Israel, Aug. 21, 2023 /PRNewswire/ -- Medical device startup NURAMI MEDICAL has received 510(k) clearance from the US Food and Drug Administration (FDA) for its electrospun nanofiber-based product, ArtiFascia® Dura Substitute, a resorbable Dural repair graft.
  • Neurosurgeries require replacing the Dura Mater, which protects the brain and cerebrospinal fluid (CSF).
  • Similar in thickness to native dura, ArtiFascia® can be effortlessly sutured, accelerating surgeon workflow and lowering healthcare costs.
  • "ArtiFascia® is a novel alternative for Dura repair, addressing dangerous CSF leaks and infections at the surgical site, while promoting Dura regeneration."

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Retrieved on: 
星期六, 六月 10, 2023
Graft-versus-host disease, Royal Melbourne Hospital, CD19, European Hematology Association, CRS, ICML, Lymphoma, NHL, Histology, NK, Toxicity, CAR, Asilomar International Conference on Climate Intervention Technologies, Patient, Mantle cell lymphoma, SAN, The Retreat, EHA, Biology, MCL, Conference, Neurotoxicity, Pharmaceutical industry, Lead

SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).
  • NKX019 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target CD19.
  • The presentations will ensure that the broader clinical and academic community has the opportunity to assess the NKX019 clinical data in a peer-reviewed format.
  • Nkarta plans to provide an update from the NKX019 program, including data from dose expansion cohorts, in 2023.

AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients

Retrieved on: 
星期五, 六月 9, 2023
CLL, Neutropenia, Rituximab, Obinutuzumab, Febrile neutropenia, Ars, Royal Melbourne Hospital, European Hematology Association, Diarrhea, German, Grade 3, ABBV, Roche, Aes, Bone marrow, OS, Cytokine, PFS, MRD, Congress, Chlorambucil, AbbVie, Patient, Anemia, Confidence interval, EHA, Hematology, Nausea, Press, Upper respiratory tract infection, Safety, Thrombocytopenia, NYSE, Venetoclax, Pneumonia, Fatigue, Pharmaceutical industry, Fine chemical, Genentech

The results are being presented during oral sessions at the European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The results are being presented during oral sessions at the European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • "These results underscore our commitment to transform how blood cancers are treated today and show that venetoclax can give patients lasting results with time off treatment."
  • New six-year follow-up results from the Phase 3 CLL14 study showcase updated outcomes in previously untreated patients with CLL and co-existing conditions.
  • "These results confirm the treatment benefits of fixed-duration venetoclax and obinutuzumab for previously untreated CLL patients with co-existing conditions."

Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings

Retrieved on: 
星期三, 四月 26, 2023
Health, Other Health, General Health, Clinical Trials, Research, Science, Biotechnology, No-scalpel vasectomy, Abstract, Male, Reproductive medicine, MBBS, ADAM, AUA, Birth, Clinical trial, Vasectomy, American Urological Association, Doctor of Philosophy, Royal Melbourne Hospital, Epworth HealthCare, MD, Patient, Azoospermia, European Association of Urology, Safety, EAU, Birth control, Pharmaceutical industry, FRACS, Urology

The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).

Key Points: 
  • The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Association of Urology (EAU) and the American Urological Association (AUA).
  • The podium presentations by Nathan Lawrentschuk at AUA and Paul Anderson at EAU highlight the early research findings on the ADAM System.
  • Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception.
  • The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

Retrieved on: 
星期一, 一月 9, 2023
Biotechnology, Technology, Health, Biometrics, Wearables, Mobile Technology, Neurology, Health Technology, Medical Devices, Mobile, Wireless, Hardware, Clinical Trials, Clinical trial, Communication, Multiple sclerosis, Partnership, Salt Lake, Stroke, University, Muscle, Royal Melbourne Hospital, Neuroprosthetics, Paralysis, BCIS, Smartphone, Brain, Telephone, Multimedia, Carnegie Mellon University, Neurology, JAMA Neurology, BCI, Digital, Trial of the century, ALS, Acquisition, Angiography, Patient, Ripple, COMMAND, Learning, Safety, Motor cortex, Mount Sinai Hospital, SWITCH, Caregiver, Mobile phone, Management, Medical imaging, Journal of NeuroInterventional Surgery, Beckman Coulter

Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.

Key Points: 
  • Synchron , an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.
  • Three out of six participants have been enrolled in the COMMAND trial, two in New York City and one in Pittsburgh.
  • For healthcare providers, patients, or caregivers interested in learning more about our ongoing US clinical trial, email: [email protected] .
  • A BCI could restore motor capability by using the cortical motor signal to bypass impaired limbs and directly control a computer.

Contraline Announces First Patients Successfully Implanted in Male Contraceptive Study

Retrieved on: 
星期四, 十一月 10, 2022
Science, Research, Surgery, Men, Health, Medical Devices, Consumer, Clinical Trials, Birth, Reproductive health, Male, Family, Multimedia, Royal Melbourne Hospital, Man, Semen, Safety, Time, Epworth HealthCare, Vasectomy, Entrepreneurship, Human, Clinical trial, Patient, CEO, ADAM, Hospital, Ted Whitten, GV, Birth control, Urology

Contraline today announced the first hydrogel-based male contraceptive implants were performed in humans in a clinical trial.

Key Points: 
  • Contraline today announced the first hydrogel-based male contraceptive implants were performed in humans in a clinical trial.
  • The procedure marks the first patient implanted in The ADAM Study, which is being conducted under Human Research Ethics Committee approval.
  • The study was supported by Contraline in addition to the Male Contraceptive Initiative.
  • Contraline is continuing the study in Australia with the eventual goal of opening a second study with a larger group of patients in the United States.

The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa

Retrieved on: 
星期二, 十月 25, 2022
Royal Melbourne Hospital, Wound healing, Journal of the American Academy of Dermatology, Acceleration, Epidermolysis bullosa, Patient, JEB, University of New South Wales, NSW, Degenerative disease, University, DEB, EB, Pain, Safety, St George's Hospital, Principal, Pharmaceutical industry, Dermatology, EU, EASE

EASE is the largest Phase 3, randomised, controlled study in Epidermolysis Bullosa (EB), that examined the efficacy and safety of Filsuvez (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB.

Key Points: 
  • EASE is the largest Phase 3, randomised, controlled study in Epidermolysis Bullosa (EB), that examined the efficacy and safety of Filsuvez (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB.
  • *
    Key outcomes from the EASE double-blind phase included:
    Professor Dedee Murrell, Head of Dept.
  • The EASE trial (NCT03068780) is the largest ever global Phase 3 trial conducted in patients with EB, performed across 58 sites in 28 countries.
  • It comprises a 3-month double-blind randomized controlled phase followed by a 24-month open-label, single-arm phase.

Covis Pharma Group Announces Two Executive Management Team Appointments

Retrieved on: 
星期一, 一月 31, 2022
Merck & Co., Bausch Health, Leadership, Marketing, Patient, Therapy, Commercial Operating System (COS), Organization, Supply chain, Sanofi, Temple University, Hotel manager, Board, General manager, International, U.S. Business Hall of Fame, Market access, Â, Company, Health, Critical care, GLOBE, Acquisition, Bristol Myers Squibb, Quality assurance, Senior, Merck, Industry, Information technology, CEDEP, Medical Affairs Bureau, Royal Melbourne Hospital, Fine chemical, Management, Pharmaceutical industry, Acceleron, Mallinckrodt, Pharmacovigilance

ZUG, Switzerland, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, today announced the joining of Michelle Lock as Chief Operating Officer, effective February 7, 2022, and the internal appointment of Sandy Loreaux as President, U.S. Business, with immediate effect. Michelle will report to Covis Pharma’s Chief Executive Officer, Michael Porter, and will be based in Zug, Switzerland. Sandy will report to Michelle and will be based in the U.S.

Key Points: 
  • - Also Announces Executive Leadership Transition with the Appointment of Sandy Loreaux as President, U.S. Business.
  • The executive leaders of the Companys Commercial, Supply Chain, Quality Assurance, Regulatory Affairs, Pharmacovigilance, and Information Technology functions will report to Michelle.
  • Michelle holds a registered nursing degree from Royal Melbourne Hospital in Australia and studied International General Management at CEDEP in France.
  • In addition, we are proud to internally appoint Sandy Loreaux, who will replace Al Tenuto, to lead our U.S. business and talented team across the country.